[go: up one dir, main page]

WO2017211922A3 - Protease-resistant mono-lipidated peptides - Google Patents

Protease-resistant mono-lipidated peptides Download PDF

Info

Publication number
WO2017211922A3
WO2017211922A3 PCT/EP2017/063905 EP2017063905W WO2017211922A3 WO 2017211922 A3 WO2017211922 A3 WO 2017211922A3 EP 2017063905 W EP2017063905 W EP 2017063905W WO 2017211922 A3 WO2017211922 A3 WO 2017211922A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease
peptides
resistant
amino acids
lipidated peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/063905
Other languages
French (fr)
Other versions
WO2017211922A2 (en
Inventor
Maria A BEDNAREK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3025592A priority Critical patent/CA3025592A1/en
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to KR1020197000408A priority patent/KR20190017017A/en
Priority to CN201780032425.2A priority patent/CN109195984A/en
Priority to AU2017277594A priority patent/AU2017277594A1/en
Priority to EP17731089.3A priority patent/EP3468987A2/en
Priority to JP2018562568A priority patent/JP2019525732A/en
Priority to MX2018014966A priority patent/MX2018014966A/en
Priority to BR112018072968-0A priority patent/BR112018072968A2/en
Publication of WO2017211922A2 publication Critical patent/WO2017211922A2/en
Publication of WO2017211922A3 publication Critical patent/WO2017211922A3/en
Priority to IL263292A priority patent/IL263292A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substituition of alternative amino acids for natural amino acids and additional amino acids added to the peptide chain has been determined to produce protease-resistant peptides.
PCT/EP2017/063905 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides Ceased WO2017211922A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR112018072968-0A BR112018072968A2 (en) 2016-06-09 2017-06-08 protease resistant monolipidated peptides
KR1020197000408A KR20190017017A (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides
CN201780032425.2A CN109195984A (en) 2016-06-09 2017-06-08 The mono- esterified peptide of protease resistant
AU2017277594A AU2017277594A1 (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides
EP17731089.3A EP3468987A2 (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides
CA3025592A CA3025592A1 (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides
MX2018014966A MX2018014966A (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides.
JP2018562568A JP2019525732A (en) 2016-06-09 2017-06-08 Protease-resistant monolipid peptide
IL263292A IL263292A (en) 2016-06-09 2018-11-26 Protease-resistant mono-lipidated peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347693P 2016-06-09 2016-06-09
US62/347693 2016-06-09

Publications (2)

Publication Number Publication Date
WO2017211922A2 WO2017211922A2 (en) 2017-12-14
WO2017211922A3 true WO2017211922A3 (en) 2018-01-18

Family

ID=59078034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/063905 Ceased WO2017211922A2 (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides

Country Status (10)

Country Link
EP (1) EP3468987A2 (en)
JP (1) JP2019525732A (en)
KR (1) KR20190017017A (en)
CN (1) CN109195984A (en)
AU (1) AU2017277594A1 (en)
BR (1) BR112018072968A2 (en)
CA (1) CA3025592A1 (en)
IL (1) IL263292A (en)
MX (1) MX2018014966A (en)
WO (1) WO2017211922A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304574B2 (en) 2017-09-22 2025-08-01 Regeneron Pharma Glucagon-like peptide-1 receptor agonists and their uses
ES2925678T3 (en) 2018-04-05 2022-10-19 Sun Pharmaceutical Ind Ltd New analogs of GLP-1
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
TW202346323A (en) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 Glp-1 and glucagon dual agonist peptides with improved biological stability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
WO2015086686A2 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
WO2016198544A1 (en) * 2015-06-10 2016-12-15 Medimmune Limited Protease-resistant lipidated glp-1 analogs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
WO2015086686A2 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
WO2016198544A1 (en) * 2015-06-10 2016-12-15 Medimmune Limited Protease-resistant lipidated glp-1 analogs

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHAE S Y ET AL: "The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 1, 21 May 2010 (2010-05-21), pages 10 - 16, XP027036550, ISSN: 0168-3659, [retrieved on 20100430] *
GREEN B D ET AL: "DEGRADATION, RECEPTOR BINDING, INSULIN SECRETING AND ANTIHYPERGLYCAEMIC ACTIONS OF PALMITATE-DERIVATISED NATIVE AND ALA8-SUBSTITUTED GLP-1 ANALOGUES", BIOLOGICAL CHEMISTRY, WALTER DE GRUYTER GMBH & CO, BERLIN, DE, vol. 385, no. 2, 1 February 2004 (2004-02-01), pages 169 - 177, XP009067701, ISSN: 1431-6730, DOI: 10.1515/BC.2004.035 *
HUI HONGXIANG ET AL: "Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON, GB, vol. 21, no. 4, 1 July 2005 (2005-07-01), pages 313 - 331, XP002559636, ISSN: 1520-7552, [retrieved on 20050426], DOI: 10.1002/DMRR.553 *
INSOO KIM ET AL: "A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 167, no. 2, 8 February 2011 (2011-02-08), pages 239 - 245, XP028160782, ISSN: 0167-0115, [retrieved on 20110215], DOI: 10.1016/J.REGPEP.2011.02.008 *
JUHO LEE ET AL: "Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 177, no. 1, 25 April 2012 (2012-04-25), pages 68 - 72, XP028498068, ISSN: 0167-0115, [retrieved on 20120504], DOI: 10.1016/J.REGPEP.2012.04.010 *
KIM S ET AL: "Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 17, 1 June 2005 (2005-06-01), pages 3597 - 3606, XP027767990, ISSN: 0142-9612, [retrieved on 20050601] *
WONHWA LEE ET AL: "Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis", BIOMACROMOLECULES, vol. 17, no. 3, 14 March 2016 (2016-03-14), pages 1160 - 1169, XP055406049, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.5b01756 *
YOUN ET AL: "Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 73, no. 1, 6 December 2006 (2006-12-06), pages 84 - 93, XP005794625, ISSN: 0006-2952, DOI: 10.1016/J.BCP.2006.09.013 *

Also Published As

Publication number Publication date
KR20190017017A (en) 2019-02-19
AU2017277594A1 (en) 2019-02-07
JP2019525732A (en) 2019-09-12
BR112018072968A2 (en) 2019-02-19
MX2018014966A (en) 2019-08-14
EP3468987A2 (en) 2019-04-17
WO2017211922A2 (en) 2017-12-14
CN109195984A (en) 2019-01-11
IL263292A (en) 2018-12-31
CA3025592A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
EP3936141A3 (en) Anti-senescence compounds and uses thereof
WO2017211922A3 (en) Protease-resistant mono-lipidated peptides
SG10201805039UA (en) Protease resistant peptides
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12017502259A1 (en) Protease-resistant lipidated glp-1 analogs
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
MX2017015927A (en) Mutated fragments of the ras protein.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2017025179A8 (en) A transglutamine tag for efficient site-specific bioconjugation
EP4374913A3 (en) Novel human serum albumin mutant
EA201792362A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CELIACIA SPRU
WO2015107363A3 (en) Mycobacterial antigen composition
PH12017501070A1 (en) Peptides and their use in the treatment of skin
EA202091007A1 (en) METHOD FOR REDUCING RESTORATION TIME OF SPRAY-DRIED PROTEIN COMPOSITIONS
HK1248248A1 (en) Broad-spectrum anti-infective peptides
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
WO2012077037A3 (en) PEPTIDES THAT MODULATE COMPLEX SASPase-FLG2
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
EA201691792A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA
WO2016089968A3 (en) Thermoreversible hydrogels from the arrested phase separation of elastin-like polypeptides
NZ744289A (en) Composition containing amino acids
WO2017017178A3 (en) Process for manufacturing a rubber composition based on natural rubber
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
WO2016091890A3 (en) Meningitidis vaccines comprising subtilinases
AU2018207318A8 (en) Immunomodulator peptide

Legal Events

Date Code Title Description
REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018072968

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 3025592

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17731089

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018562568

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197000408

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017731089

Country of ref document: EP

Effective date: 20190109

ENP Entry into the national phase

Ref document number: 2017277594

Country of ref document: AU

Date of ref document: 20170608

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018072968

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181108